---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-26-000018"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:30:11.806293+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics reports FY2025 net loss of $74.6M, cash $189.9M; pipeline data catalysts for 2026

## Summary
- Net loss $74.6M in 2025 vs $66.9M in 2024; revenue flat at $149.5M; cash $189.9M down from $201.7M.
- Phase 1 data for MGC026 (B7-H3 ADC) expected mid-2026; MGC028 (ADAM9 ADC) data in H2 2026.
- LINNET study of lorigerlimab under partial clinical hold; update expected mid-2026. IND for MGC030 on track for Q3 2026.
- Cash runway guidance extended into late 2027 based on current cash and partner payments.
- R&D expenses down 17% to $147.2M; SG&A down 45% to $39.2M due to cost reductions.

## SEC filing metadata
- accession: 0001125345-26-000018
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/0001125345-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/mgnx-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-26-000018
- JSON: https://secwatch.observer/filing/0001125345-26-000018.json
- Plain text: https://secwatch.observer/filing/0001125345-26-000018.txt

## Key facts
- Earnings Releases
  MACROGENICS INC reported the year ended December 31, 2025 results: revenue $149.5 million.
  - Period: the year ended December 31, 2025
  - Revenue: $149.5 million
  - Result: reported results
  source text: cash equivalents and marketable securities balance as of December 31, 2025, was $189.9 million, compared to $201.7 million as of December 31, 2024. • Revenue : Total revenue was $149.5 million for the year ended December 31, 2025, compared to $150.0 million for the year ended December 31, 2024. Total revenue included contract manufacturing revenue of $52.6 million for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/0001125345-26-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.